Impact of Perinatal Exposure to SARS-CoV-2 Infection on Early Health Outcomes among Infants Born from 2020 to 2021 in British Columbia, Canada
Table 3
Early health outcomes and prescription medication needs in the first 12 months after birth among infants with and without perinatal exposure to SARS-CoV-2.
Infants in exposed cohort (n = 480)
Infants in non‐exposedcohort (n = 1904)
Odds ratio (95% CI)†
≥1 diagnosis (in- and outpatient combined)
Any
78 (16.25%)
293 (15.39%)
1.08 (0.81, 1.43)
General conditions (failure-to-thrive and infantile colic)
<5
<5
Unable to estimate
Infectious diseases
42 (8.75%)
138 (7.25%)
1.23 (0.86, 1.78)
Respiratory
25 (5.21%)
63 (3.31%)
1.62 (1.00, 2.63)
Bacterial (non‐respiratory)
19 (3.96%)
67 (3.52%)
1.14 (0.68, 1.92)
Viral (non‐respiratory)
<5
12 (0.63%)
1.00 (0.28, 3.62)
Allergic diseases
28 (5.83%)
125 (6.57%)
0.88 (0.57, 1.36)
Atopic dermatitis
21 (4.38%)
108 (5.67%)
Allergic rhinitis
<5
11 (0.58%)
Anaphylaxis
<5
10 (0.53%)
Endocrine disorders
8 (1.67%)
12 (0.63%)
2.67 (1.09, 6.52)
Hypoglycemia
7 (1.46%)
8 (0.42%)
Renal conditions
<5
17 (0.89%)
0.46 (0.11, 2.00)
Other diseases (conjunctivitis)
12 (2.50%)
32 (1.68%)
1.54 (0.77, 3.08)
≥1 drug type by therapeutic class (outpatient only)
Any
32 (6.67%)
184 (9.66%)
0.66 (0.44, 0.98)
Eye, ear, nose, and throat preparations
Anti-infectives
9 (1.88%)
27 (1.42%)
1.35 (0.62, 2.93)
Skin and mucous membrane preparations
Anti-infectives
8 (1.67%)
51 (2.68%)
0.61 (0.28, 1.31)
Anti-inflammatory agents
13 (2.71%)
88 (4.62%)
0.57 (0.31, 1.04)
Unclassified therapeutic agents
<5
22 (1.16%)
0.55 (0.16, 1.82)
n values < 5 not reported. †The effect estimate for all outcomes was obtained by comparing exposed vs. non‐exposed cohorts. Significant odds ratio (i.e., does not cross 1.0 in 95% CI).
